NCT04528706

A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (estimated)
• Sponsor: Minoryx Therapeutics, S.L. · Industry
• Sex: Male
• Age: 2 Years – 12 Years
• Healthy volunteers: Not accepted

Summary

An Open-Label, multicenter study in male pediatric patients with cerebral x-linked adrenoleukodystrophy (cald) to assess the effects of MIN-102 treatment on disease progression prior to human stem cell transplant (HSCT)

Conditions

• Cerebral Adrenoleukodystrophy

Interventions

Type	Name	Description
DRUG	MIN-102	Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.

Timeline

• Start date: 2019-09-13
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2020-08-27
• Last updated: 2023-07-18

Locations

5 sites across 4 countries: Argentina, France, Germany, Spain